

Index

- A**
Acute lymphocytic leukemia, 5
Adrenal tumors, 8
Adrenocortical tumors (ACT), 8
African Histoplasmosis, 83, 84
Alkaline phosphatase (ALP) staining, 251, 254, 255
Alpha fetoprotein (AFP), 7–9, 278, 280, 283
Alveolar rhabdomyosarcoma, 10, 11, 13, 14, 35, 44, 53, 54, 152
Anaplastic ependymoma, 342
Anaplastic large cell lymphoma (ALCL), 6, 305, 319–322
 ancillary techniques, 320, 322
 cytomorphology
 histiocytic variant, 320, 321
 nuclear shapes and prominent nucleoli, 320
 small cell variant, 320
 differential diagnosis, 322
Anaplastic lymphoma kinase (ALK), 320, 322
Angiomatoid fibrous histiocytoma (AFH), 227
 ancillary techniques, 229
 cytologic features, 228
 cytomorphology, 227–228
 differential diagnosis, 229
Aspergillosis, 89, 90
Aspergillus, 89
Atypical teratoid/rhabdoid tumor (AT/RT), 339, 342
 ancillary techniques, 344
 cytomorphology, 343
- B**
Bacteria
 Actinomyces and *Nocardia*, 70
 Bartonella henselae, 63
 Chlamydia species, 63
 Klebsiella rhinoscleromatis, 69
 malacoplakia, 70
 mycobacteria, 64–66
 pyogenic bacteria, 61–62
 spirochetes, 67–68
Benign follicular nodule, 291
 ancillary techniques, 291
 differential diagnosis, 291
Bethesda System for Reporting Thyroid Cytopathology (BSRTC), 290, 293
Biliary and pancreatic trematodes, 79
Biphasic synovial sarcoma, 259–261
Blastemal tumors
 hepatoblastoma, 197–202
 nephroblastoma, 179–188
 neuroblastic tumors, 171–178
 pancreatoblastoma, 195–196
 pleuropulmonary blastoma, 192–194
 retinoblastoma, 189–191
Bone tumors, 10
Boreliosis, 68
Borrelia, 68
Botryoid rhabdomyosarcoma, 53
Branchial cleft cyst (BCC), 117, 120
 ancillary techniques, 120
 cytomorphology, 117–119
 differential diagnosis, 120
Burkitt lymphoma (BL), 308, 310, 311
 ancillary techniques, 309, 312
 cytomorphology
 monotonous round nuclei and lymphoglandular bodies, 308, 311
 multiple nucleoli and cytoplasmic lipid vacuoles, 308, 310
 starry sky pattern, 308
 differential diagnosis, 312
 immunocytochemistry/flow cytometry, 309
 Ki-67/MIB1 positive nuclei, 309, 312
 types of, 308
- C**
Calinex®, 24–26
Cat scratch disease, 63
Central nervous system (CNS), 326, 327, 329–332, 334, 335, 339, 340, 342–346
 choroid plexus tumors, 338
 cytopathology, 325
 embryonal tumors
 atypical teratoid/rhabdoid tumor, 342, 343
 medulloblastoma, 339, 340, 342
 pineal region tumors, 346
 suprasellar tumors, 344, 345
 ependymoma, 335, 336
 gliomas
 ganglion cell tumors, 330, 331
 high-grade gliomas, 334, 335
 pilocytic astrocytoma, 326, 327, 329
 pleomorphic xanthoastrocytoma, 332
 subependymal giant cell astrocytoma, 334
 histopathological subtypes, anatomic site, 326
 neuroimaging, 325

- Cestodes
 hepatic hydatidosis, 81
 hydatidosis, 81
 Taenia, 82
- Children and adolescents lymphomas, 305
- Choriocarcinoma, 280
 cytotrophoblasts, 280, 283
 syncytiotrophoblasts, 280, 282
- Choroid plexus tumors, 338
 differential diagnosis, 339
 epithelial regular cells, 338
 papillary architecture, 338, 339
- Chromomycosis*, 88, 91
- Chronic lymphocytic thyroiditis
 differential diagnosis, 291, 292
 juvenile variant, 291
 papillary thyroid carcinoma, 291, 292
- Classical Hodgkin lymphoma, 305
 differential diagnosis, 308
 RS cells, 306
- Cortical neurons, 332
- Craniopharyngiomas (CP), 344, 345
 ancillary techniques, 344
 cytomorphology
 macrophage infiltrates, 344, 345
 rhomboid cholesterol crystals, 344
 scattered epithelial clusters, 344, 345
 differential diagnosis, 345
- Cryptococcus neoformans*, 83, 85, 86
- Cushing's syndrome, 8
- Cysticercosis, 82
- D**
- Dermatofibrosarcoma protuberans (DFSP), 38–40, 222
 ancillary techniques, 222
 cytologic features of, 224
 differential diagnosis, 225, 226
 fine and homogeneous chromatin and inconspicuous nucleoli, 222, 224
 uniform spindle cells, 223
- Desmoids/fibromatoses, 205
 ancillary techniques, 211
 cytological features, 206, 210
 differential diagnosis, 211
 fibromatosis colli, 206, 209
 juvenile hyaline fibromatosis, 206, 210
 long fascicular cohesive fragment, 206
 paucicellular collagenous stroma and damaged fibroblasts, 207
 paucicellular stroma and regenerating muscle, 208
 pleomorphic spindled and epithelioid fibroblasts, 206, 207
 superficial fibromatosis, 206, 208
- Desmoplastic round cell tumor, 35, 37
- Desmoplastic small round cell tumor (DSRCT), 47, 153, 158
 ancillary techniques, 154
 desmoplastic stroma, 155
 differential diagnosis, 154, 158
 dispersed tumor cells and naked nuclei, 153
 moderately well formed rosette and dissociated cells, 155
 monomorphic population of cells, 153, 156
 Papanicolaou staining, 154, 157
 polymorphic nuclei, marked anisonucleosis and paranuclear density, 154, 156
 tissue fragments, 154
- Diff-Quik staining, 28
- Diffuse astrocytoma, 326
- Diffuse intrinsic pontine glioma (DIPG), 335
- Diffuse large B-cell lymphoma (DLBCL), 312, 313
 ancillary techniques, 314
 cytomorphology
 high cellularity, 312, 313
 prominent nucleoli, 312, 313
 differential diagnosis, 314
 gene expression profiles, 312
 immunohistochemical algorithm, 312
- Diffuse midline gliomas, 334
 ancillary techniques, 335
 cytomorphology, 334, 335
 differential diagnosis, 335
- Dirofilaria immitis*, 77
- E**
- Embryonal carcinoma
 Papanicolaou staining, 280, 282
 scant cytoplasm and prominent nucleoli, 280, 281
 tight cell clusters and dissociated cells, 280, 281
- Embryonal rhabdomyosarcoma, 53–54
- Embryonal tumors
 atypical teratoid/rhabdoid tumor, 342, 343
 medulloblastoma, 339, 340, 342
 pineal region tumors, 346
 suprasellar tumors, 344, 345
- Emla®, 24, 25
- Enlarged cervical nodes, 5
- Entamoeba histolytica*, 73
- Ependymomas (EPs), 330, 335
 ancillary techniques, 338
 angiocentric organization, 335, 336
 differential diagnosis, 338
 fibrillary processes, 335, 336
 myxopapillary variant, 335, 337
 tadpole-shaped cytoplasm, 335, 337
- Epidermoid cyst, 346
- Epithelial and epithelial-like tumors
 germ cell tumors, 272–283
 malignant melanoma, 283–287
 pilomatricoma, 269–270
 salivary tumors, 271–272
 undifferentiated carcinoma of nasopharyngeal type, 267–268
- Epithelioid sarcomas (ES), 245–247
 ancillary techniques, 245
 cytomorphology
 epithelioid cells mimicking carcinoma, 247
 histological sections, 247
 polymorphous epithelioid cells, 245, 246
 polymorphous epithelioid, rhabdoid features, 245, 246
 differential diagnosis, 245
 distal subtype, 245
 proximal subtype, 245
- Epstein-Barr virus (EBV), 6, 71, 305
- ES. *See* Epithelioid sarcomas (ES)
- Ewing sarcoma
 adjuvant radiotherapy, 10
 CIC-DUX4/BCOR-CCNB3 sarcomas, 52, 53
 common sites, 10
 diagnosis, 10
 incidence, 10
 molecular alterations, 16, 17
 plasmacytoid cells, 31
 round cells, 35, 36, 38
 STAG2 mutations, 23

- Ewing sarcoma/primitive neuroectodermal tumor family (EWS/PNET), 140, 147, 152
 accidental groupings/chance formations, round cells in, 147
 ancillary techniques, 150, 151
 differential diagnosis, 150, 152
 glycogen vacuoles, 150
 incidence rate, 147
 myxoid material, 150, 151
 plasmacitoid cells, 147, 149
 rosettes, 147, 148
 small nucleoli and scant cytoplasm, 147, 149
 tight cell group, 147, 148
- Excisional biopsy, 1
- Extracerebral pediatric tumors
 alveolar rhabdomyosarcoma, 11, 13, 14
 clinical examination, 11
 conventional radiography, 11
 Doppler analysis, 11
 FNA, 14, 15
 Gardner syndrome, 11, 13
 left adrenal neuroblastoma, 11, 13
 MRI technique, 11
 palpation-guided cytology, 11
 radiological diagnosis, 11
 surgical and core needle biopsies, 13, 14
 ultrasound, 11
- F**
- Familial nonmedullary thyroid carcinoma, 290
Fasciola hepatica, 79
 Fat necrosis (FN), 108, 111
 ancillary techniques, 108
 cytomorphology, 108–110
 differential diagnosis, 108
 imaging features of, 108
- Fetal hepatoblastoma, 27
- Fibromatosis colli, 209
- Fibrous hamartoma of infancy (FHI), 219
 ancillary techniques, 220
 bland spindle cells, tight cluster of, 221
 cytological features of, 221
 differential diagnosis, 220
 histogenesis of, 219
 mature fatty tissue and bland spindle cells, 220
 naked nuclei and fragment of collagenous tissue, 221
- Filamentous hyphae, 90
- Fine-needle aspiration (FNA), 1, 158, 159, 206, 232
 cytologic material, 26
 desmoid-type fibromatosis (*see* Desmoids/fibromatoses)
 diagnostic accuracy, sensitivity and specificity, 303
 DSRCT (*see* Desmoplastic small round cell tumor (DSRCT))
 embryonal carcinoma, 280
 extra cellular material, 26
 extracerebral pediatric tumors, 14
 germinomas, 273
 material, 16
 neuroblastoma, 51, 52
 PMH (*see* Pseudomyogenic hemangioendothelioma (PMH))
 of thyroglossal duct cyst, 291
 RT (*see* Rhabdoid tumor (RT))
 yolk sac tumor, 277, 278
- Flow cytometry (FC) technique, 22
- Follicular adenoma, 292, 293
 ancillary techniques, 292
 differential diagnosis, 293
- Follicular carcinoma, 293, 294
 ancillary techniques, 293, 294
 cytological features of, 293
 differential diagnosis, 294
 histopathologic variant of, 293
 molecular diagnostics, 294
- Follicular lymphoma, 314
- Foreign body granuloma (FBG), 112, 116
 ancillary techniques, 116
 cytomorphology, 112–115
 differential diagnosis, 116
- Frantz tumor, 7
- G**
- Ganglioglioma, 326
- Ganglion cell tumors, 330, 331
 ancillary techniques, 330
 cytomorphology
 eosinophilic granular bodies, 330, 331
 eosinophilic prominent nucleolus, 330
 lymphocytic perivascular infiltrates, 330, 331
 differential diagnosis, 330
- Ganglion cell-origin tumors, 8
- Ganglion cyst (GC), 120–122
- Ganglioneuroblastoma
 ganglion and giant cells, 175
 neuroblasts and maturing cells, 175
 schwannian tissue, 176
- Ganglioneuroblastoma intermixed (GNBi), 49, 50
- Ganglioneuroblastoma nodular (GNBnod), 49, 50
- Ganglioneuroma, 49, 50
- Gardner syndrome, 11, 13
- Germ cell tumors (GCT), 8, 9, 272–275, 346
 choriocarcinoma, 280, 282, 283
 differential diagnosis, 280, 283
 embryonal carcinoma, 280–282
 histologic classification, 272
 incidence rate of, 272
 predisposing factors, 272
 seminomas and dysgerminomas, 273, 275
 symptoms of, 272
 teratoma, 272
 cell block, 274
 fat and mesodermal structures, 272, 273
 immature teratoma, 274
 somatic type malignancy, neuroendocrine carcinoma, 272, 275
 tubules and epithelial elements, 273
 yolk sac tumors, 277–280
- Germinoma, 273, 275, 346
 cytomorphology, 346
 differential diagnosis, 346
- Giant cell glioblastoma, 334
- Giant cell reparative granuloma (GCRG), 129–131
- Gliomas, 326, 327, 329, 330, 332–334
 ganglion cell tumors, 330
 ancillary techniques, 330
 cytomorphology, 330, 331
 differential diagnosis, 330, 332
 high-grade gliomas, 334, 335
 pilocytic astrocytoma
 ancillary techniques, 326
 cytomorphology, 326–329
 differential diagnosis, 326, 330
 pleomorphic xanthoastrocytoma, 332

- Gliomas (*cont.*)
 ancillary techniques, 332, 333
 cytomorphology, 332, 333
 differential diagnosis, 334
 subependymal giant cell astrocytoma, 334
 cytomorphology, 334
 differential diagnosis, 334
 Grave's disease, 291, 299
- H**
 Helminthes, 77–82
 Hematoxylin-and-eosin safran (HES), 26, 181, 207, 247, 250, 273
 Hepatic hydatidosis, 81
 Hepatic tumors, 7
 Hepatoblastoma (HB), 7, 197, 202
 ancillary techniques, 200
 cytologic features, 200
 differential diagnosis, 200–202
 embryonal variant, 197
 epithelial clusters, 201
 fetal variant, 198
 loose connective tissue and epithelial cells, 201
 osteoid, 200
 small cells, 199
 Hepatocellular carcinoma (HCC), 7
 High-grade osteosarcoma
 alkaline phosphatase staining, 254
 calcifications and mitoses, 250
 cell block section, 255
 chondro-myxoid background, 251, 253
 cytological features, 248, 251
 multinucleated tumor cells, 249
 pleomorphic rounded, ovoid and polygonal tumor cells, 249
 pleomorphic tumor cells, 248, 250
 tumor matrix, 252
Histoplasma capsulatum, 83–85
 Hodgkin lymphoma (HL), 5, 305, 306, 308
 ancillary techniques, 307–308
 cytomorphology
 lymphocyte predominant HL, nodular, 308
 of classical HL, 306, 307
 differential diagnosis, 308
 incidence of, 305–306
 symptoms and signs, 306
 types, 305
 Human papilloma virus (HPV), 67, 70
 Hydatidosis, 81
 Hypercortisolism, 8
 Hyperplastic (adenomatoid) nodules, 291
 Hyphal fungi, 88–91
- I**
 Immature rhabdomyoblasts, 138–140
 Immediate nephrectomy, 9
 Immunocytochemistry (ICC), 21, 22
 Infantile fibrosarcoma, 257, 258
 ancillary techniques, 258
 clinical presentation, 257
 cytologic features, 258
 cytomorphology
 fusiform nuclei, 258
 three dimensional clusters and fascicles, 257
 differential diagnosis, 258
 Infectious tumor-like lesions
Actinomyces and *Nocardia*, 70
 cat scratch disease, 63
 clinical conditions, 59–60
 EBV, 71
 fungi, 83–92
 gram positive and gram negative, 61, 62
Herpesvirus 8, 72
 HPV, 70
 LGV, 63
 malacoplakia, 70
 mycobacteria, 64–66
 parasites, 73–82
 spirochetes, 67–68
 Inflammatory myofibroblastic tumors (IMT), 8, 9
 International Neuroblastoma Pathology Classification (INPC), 49, 51
- J**
 Juvenile hyaline fibromatosis, 206, 210
- K**
 Kaposi disease, 72
Klebsiella rhinoscleromatis, 69
- L**
 Langerhans cell histiocytosis (LCH), 121, 123–128
 Left adrenal neuroblastoma, 11, 13
Leishmania, 74–75
 Lipoblastoma, 217, 219
 ancillary techniques, 217
 branching capillaries, fat tissue, 218
 cytological features, 218
 differential diagnosis, 217
 fatty tissue, abundant myxoid matrix, 217
 Low-grade superficial connective tumors
 angiomatoid fibrous histiocytoma, 227–229
 dermatofibrosarcoma protuberans, 222–226
 desmoids/fibromatoses, 205–211
 fibrous hamartoma of infancy, 219–221
 lipoblastoma, 217–219
 pseudomyogenic hemangioendothelioma, 229–232
 schwannoma, 232–240
 solitary fibrous tumor, 211–216
 Lung histioplasmoma, 83
 Lung mass, 70
 Lymphadenopathies (LAPs), 5, 13, 14, 306
 Lymph node tuberculosis, 64
 Lymphoblastic lymphomas (LBL), 314, 315, 317
 ancillary techniques, 318–319
 cytomorphology
 larger cells, irregular and indented nuclei, 315, 317, 318
 monotonous cell population, 314–316
 differential diagnosis, 319
 treatment and cytology evaluation, 314
 Lymphogranuloma venereum (LGV), 63
 Lymphomas
 anaplastic large cell lymphoma, 319–322
 Burkitt lymphoma, 308–312
 diffuse large B-cell lymphoma, not otherwise specified, 312–314
 epidemiology of, 305
 follicular, 314
 Hodgkin lymphoma, 305–308
 post-transplant lymphoproliferative disease, 322–323

- precursor T cell lymphoma and precursor B cell lymphoma, 314–319
T-cell/histiocyte-rich large B cell lymphoma, 314
- M**
- Malacoplakia, 70
- Malignant melanoma (MM), 283–284
ancillary techniques, 287
cell block, 286
cellular smears, dispersed cells, 284
differential diagnosis, 287
epithelioid cell variant, 285
intracytoplasmic melanin, 286
large nucleoli, 285
- Malignant peripheral nerve sheath tumor (MPNST), 255, 256
ancillary techniques, 257
cytomorphology, 256
differential diagnosis, 257
- Malignant rhabdoid tumor (MRT), 53, 54
- Malignant small round cell tumors (MSRCT), 47, 48, 51
- Mature B cell lymphomas. *See* Lymphomas
- Mature rhabdomyoblasts, 138
- May-Grünwald Giemsa (MGG) stains, 26, 27
- Medullary thyroid carcinoma (MTC), 299–300
ancillary techniques, 300
differential diagnosis, 300
family history of, 290
- Medulloblastomas (MB), 339–342
ancillary techniques, 342
cytomorphology
normal internal granule cells, 339, 341
nuclear atypia, 342
nuclei, 339, 340
small neoplastic cells, diffuse sheets of, 339, 340
smear preparation, 339, 341
differential diagnosis, 342
- Mesenchymal chondrosarcoma (MCS), 161, 164
ancillary techniques, 164
dense tissue fragments, 161
differential diagnosis, 164
dissociated, predominantly round cells, 163
moderate/abundant chondroid stroma, 161, 162
monomorphous cell population, 163
- Mesoblastic nephroma, 187
- Metanephric adenoma, 186
- Metastatic amelanotic melanoma, 314
- Metastatic small cell carcinoma, 314
- Mikulicz cells, 69
- Moderately differentiated rhabdomyoblasts, 138
- Monophasic synovial sarcoma, 259, 260
- Mucoepidermoid carcinoma, 271
- Mucor*, 90
- Multiple endocrine neoplasia 2A (MEN2A), 290
- Multiple endocrine neoplasia 2B (MEN2B), 290
- Muscle regeneration and repair (MRR), 103
ancillary techniques, 103
cytomorphology, 103–107
differential diagnosis, 103
normal and degenerating fragments, 104
nuclei and eosinophilic cytoplasm, 105
strap-like regenerating muscle cell, 105
- Mycetoma, 91, 92
- Mycobacteria
atypical mycobacteria, 66
Mycobacterium Leprae, 66
Mycobacterium tuberculosis, 64–65
- Myositis ossificans (MO), 98, 103
ancillary techniques, 103
atypical fibroblasts/myofibroblasts, 102
differential diagnosis, 103
dissociated fibroblasts/myofibroblasts, 99
incidence rate of, 98
osteoblasts, 100
stroma and spindle shaped fibroblasts, 101
- N**
- Nematodes, 77, 78
- Neoadjuvant chemotherapy, 7
- Nephroblastoma, 179
anaplastic component, 184
anaplastic nephroblastoma, 51
ancillary techniques, 185
blastemal cells, 32, 33
cytologic features, 185
diagnosis, 51
differential diagnosis, 185, 186
dispersed blastemal cells and clustering epithelial cells, 180
fine-needle aspiration biopsy, 51, 52
mesenchymal component and blastemal cells, 182
poorly differentiated blastemal cells, 179
types, 51
- Neuroblastic tumors, 171, 177
ancillary techniques, 177
cytologic features, 177
differential diagnosis, 177
ganglion and giant cells, 175
GD2 positivity of neuroblasts, 176
maturing neuroblastoma, 173
neuroblasts and maturing cells, 175
neuropil, 173
poorly differentiated neuroblastoma, 172
rosettes and central neuropil, 174
schwannian tissue, 176
well differentiated neuroblasts, 172, 173
- Neuroblastoma, 1, 6, 8
blastemal cells, 32, 34
calcifications and necrosis, 45
GD2 positivity of neuroblasts, 176
maturing neuroblastoma, 173
neuropil, 38, 43
neuropil and well differentiated neuroblasts, 173
peripheral neuroblastic tumors, 49, 50
poorly differentiated neuroblastoma, 172
rosettes and central neuropil, 174
- Neuro-endocrine tumors, 7
- Nodular fasciitis (NF), 92, 98, 211, 225, 229, 230, 232, 240
ancillary techniques, 93
atypical myofibroblasts, 96
differential diagnosis, 97
fibroblasts/myofibroblasts, 93, 95
incidence rate of, 92
large tissue fragment, 94
- Nodular lymphocyte predominant Hodgkin lymphoma, 305, 308
- Non-Hodgkin's lymphomas (NHL), 5–7
- Non-infectious tumor-like lesions
branchial cleft cyst, 117–120
fat necrosis, 108–111
foreign body granuloma, 112–116
ganglion cyst, 120–122
GCRG, 129–131

- Non-infectious tumor-like lesions (*cont.*)
 LCH, 121, 123–128
 muscle regeneration and repair, 103–107
 myositis ossificans, 98–103
 nodular fasciitis, 92–98
 RDD, 131–134
- Non rhabdomyosarcoma soft tissue sarcomas (NR-STs), 9
- Non-round cell sarcomas
 epithelioid sarcomas, 245–247
 infantile fibrosarcoma, 257, 258
 MPNST, 255–257
 osteosarcoma, 248–255
 synovial sarcoma, 259–264
- Non-tuberculosis infection, 66
- Normal choroid plexuses, 339
- O**
- Osteosarcoma, 10, 248
 alkaline phosphatase staining, 251, 254
 calcifications and mitoses, 250, 251
 chondro-myxoid background, 251, 253
 cytological features, 248, 251
 differential diagnosis, 254
 multinucleated tumor cells, 249, 251
 pleomorphic rounded, ovoid and polygonal tumor cells, 248, 249
 pleomorphic tumor cells, 248
 small cell osteosarcoma, 251, 253
 tumor matrix, 252
- Ovarian malignant tumor, 8
- P**
- Palpable orbital tumor, 26
- Palpable parotid metastasis, 24
- Palpable parotid tumor, 25
- Palpable rhabdomyosarcoma, 24, 25
- Pancreatic tumors, 7
- Pancreatoblastoma (PB), 7, 195, 196
 ancillary techniques, 196
 cohesive epithelial cells, 195
 core-needle biopsy, 195, 196
 cytologic features, 196
 differential diagnosis, 196
- Papanicolaou stain, 26, 29
- Papillary microcarcinoma, 298
- Papillary thyroid carcinoma (PTC), 294–296
 BRAF mutations, 298
 columnar cell variant, 296, 298
 cystic variant, 296, 298
 differential diagnosis, 298–299
 diffuse sclerosing variant, 296
 follicular variant, 296, 297
 intranuclear cytoplasmic pseudoinclusions, 295
 macrofollicular variant, 296
 miRNA expression changes, 298
 monolayer sheets of tumor cells, 296
 oncocytic (Hürthle cell) variant, 296, 297
 papillary microcarcinoma, 298
 RAS mutations, 298
 RET/PTC rearrangement, 298
 swirling spheroid cell cluster, 295
 tall cell variant, 296
 TRK rearrangement, 298
- Paravertebral neuroblastoma, 11
- Pediatric tumors, 24, 325
- ACVR1 mutations, 23
 at age, 3, 4
 air-dried smears, 24, 25
 ALK alterations, 23
 anucleated squamous cell, 29
 benign lesions, 47
 blastemal cells, 32–34
 BRAF^{V600E} mutations, 23
 calcifications, 45
 cellular and stromal components, 45, 46
 classic Sanger sequencing, 19, 20
 classification, 47
 clinical syndromes, 3
 clinical trials, 23
 CNS (*see* Central nervous system (CNS))
 core needle biopsy, 2, 24–26
 cytological diagnosis, 24
 cytological sampling, 25, 26
 DNA sequencing, 19
 epidemiology, 3
 epithelial cells, 29, 30
 epithelioid cells, 31, 32
 Ewing sarcoma (*see* Ewing sarcoma)
 EWSR1 fusion, 23
 excisional surgical biopsy, 24
 flow cytometry, 22
 FNA (*see* Fine-needle aspiration (FNA))
 hepatoblastoma, 44, 45
 immunocytochemistry, 21, 22
 in situ hybridization, 18, 19
 KIAA1549-BRAF fusions, 23
 local anaesthesia, 26
 malignant lesions, 47
 molecular alterations, 16–18
 MYCN amplification, 23
 nephroblastoma (*see* Nephroblastoma)
 next-generation sequencing, 20, 21
 non-palpable lesions, 26
 open biopsy, 16
 osteosarcoma, 44
 palpable lesions, 26
 paraffin-embedded cell blocks, 26, 28
 PCR, 19, 20
 peripheral neuroblastic tumors (*see* Peripheral neuroblastic tumors)
 primary tumor site, 3, 4
 renal tumors, 51, 52
 rhabdomyosarcoma (*see* Rhabdomyosarcoma)
 ROSE, 23, 28
 round cells, 35–38
 RT-PCR, 19, 20
 spindle cells, 38–43
 stroma, 38
 therapeutic targets, 23
- Pelvic tumors, 8, 9
- Peripheral neuroblastic tumors
 ganglioneuroblastoma intermixed, 49, 50
 ganglioneuroblastoma nodular, 49, 50
 ganglioneuroma, 49, 50
 histoprognostic, 49, 51
 International Neuroblastoma Pathology Classification, 49, 51
 neuroblastoma, 49, 50
 risk grouping, 49
 schwannian cell component, 51
- Peritoneal mesotheliomas, 7
- Peritoneal tumors, 7
- Phaehyphomycosis*, 91

- Pheochromocytoma, 8
- Pigmented hyphae, 91
- Pilocytic astrocytoma (PA), 326–330
 - ancillary techniques, 326
 - cytomorphology
 - bipolar processes, 326, 327
 - corkscrew-like shape, 326, 328
 - eosinophilic granular bodies, 326, 329
 - Rosenthal fibers, 326, 328
 - thicker cytoplasmic processes, 326, 327
 - differential diagnosis, 326, 330
- Piloid gliosis, 326
- Pilomatricoma (PMC), 269–270
 - calcifications, 270
 - ghost cells and squamous debris, 269
 - giant cell, 269
 - round cells, 270
- Pineoblastoma, 346
- Pituitary adenomas, 345
- Plague, 62
- Pleomorphic adenoma, 271
- Pleomorphic xanthoastrocytoma (PXA), 332, 333
 - ancillary techniques, 332
 - cytomorphology
 - glial fibrillary processes, 332, 333
 - multinucleated bizarre cells, 332
 - nuclear pleomorphism, 332, 333
 - differential diagnosis, 334
- Pleuropulmonary blastoma, 44, 192, 194
 - ancillary techniques, 192
 - cohesive clusters and nuclear molding, 193
 - cytologic features, 194
 - differential diagnosis, 194
 - histological classification, 192
 - spindle-shaped mesenchymal cells, 193
- Pneumocystis*, 86
- Pneumocystis jiroveci*, 86
- Pneumocystosis, 86
- Polymerase chain reaction (PCR), 19, 20, 63
- Poorly differentiated round cell synovial sarcoma (PDRCSS), 165–167
 - differential diagnosis, 165, 167
 - dissociated cells, 167
 - dissociated round cells, 165
 - rosette-like group of cells, 165
 - round cell population, high N/C ratio, 166
- Poorly differentiated thyroid carcinoma, 300, 301
 - ancillary techniques, 301
 - differential diagnosis, 301
- Post-transplant lymphoproliferative disease (PTLD)
 - ancillary techniques, 323
 - cytomorphology, 322–323
 - differential diagnosis, 323
 - early-lesions, 322
 - HL-like PTLD, 322
 - monomorphic PTLD, 322
 - polymorphic PTLD, 322
- Primary mediastinal large B cell lymphoma, 314
- Protozoa
 - Entamoeba histolytica*, 73
 - helminthes, 77–82
 - Leishmania*, 74–75
 - Toxoplasma gondii*, 76
- Pseudomyogenic hemangioendothelioma (PMH), 229
 - ancillary techniques, 232
 - cytological features, 231
 - differential diagnosis, 232
 - dispersed spindle and plump cells, 231
 - size of, 229
 - spindle cells, fusiform and ovoid nuclei, 230
- Pseudosarcomatous lesions, 205, 232
- Pulmonary trematodes, 79
- R**
- Rapid on-site evaluation (ROSE), 1, 23, 28
- Reed-Sternberg (RS) cells, 306, 307
- Renal candidosis, 87
- Renal clear cell sarcoma, 186
- Renal tumors, 9, 51, 52
- Retinoblastoma, 189
 - ancillary techniques, 189
 - cytologic features, 191
 - differential diagnosis, 191
 - Flexner-Wintersteiner rosettes, 191
 - small, round tumor cells, 189
 - V-like nuclei, 190
- Reverse transcriptase-polymerase chain reaction (RT-PCR), 19, 20
- Rhabdoid tumor (RT), 31, 32, 159, 161
 - ancillary techniques, 160
 - differential diagnosis, 160
 - dissociated cells, 159
 - rhabdoid cells, eccentric nuclei, 160
 - small round cells, scant cytoplasm, 159, 160
- Rhabdomyosarcoma (RMS), 9, 137–146, 160
 - alveolar rhabdomyosarcoma, 53, 54
 - alveolar RMS
 - desmin positivity, 145
 - dissociated, poorly and moderately differentiated rhabdomyoblasts, 140, 142
 - multinucleated rhabdomyoblast, 140, 144
 - naked nuclei, 140, 144
 - plasmacytoid appearance, 140, 143
 - ancillary techniques, 140, 145
 - botryoid rhabdomyosarcoma, 53
 - differential diagnosis, 140, 145
 - embryonal RMS, 53, 138, 139
 - botryoid and spindle Cell RMS, 139, 141
 - tissue fragments, 140
 - immature rhabdomyoblasts, 138
 - malignant rhabdoid tumor, 53, 54
 - mature rhabdomyoblasts, 138
 - moderately differentiated rhabdomyoblasts, 138
 - prognostic significance, 137
 - round cells, 35
 - spindle cell rhabdomyosarcoma, 54
- Rhinosporidium seeberi*, 88
- Rhinosporidiosis, 88
- Risk-stratified therapy, 8
- Rosai-Dorfman disease (RDD), 131–134
- Rosenthal fibers, 326, 328, 330
- Round cell sarcomas, 24
 - desmoplastic small round cell tumor, 153–158
 - EWS/PNET, 147–152
 - mesenchymal chondrosarcoma, 161–164
 - PDRCSS, 165–167
 - rhabdoid tumor, 159–161
 - rhabdomyosarcoma, 137–146
- S**
- Sacro-coccygeal teratoma, 9

- Salivary tumors, 271–272
 mucoepidermoid carcinoma, 271
 pleomorphic adenoma, 271
- Schistosomiasis, 80
- Schwannoma, 232
 ancient changes, 233, 238
 ancillary techniques, 239
 cell block, 239
 cohesive fascicles, spindle cells in, 233
 cytological features, 239
 differential diagnosis, 240
 distinctive Verocay bodies, 233, 236, 237
 fishhook-like appearance, 233, 235
 nuclear pleomorphism, 237
 scant cellularity and myxoid/fibrillary background, 233, 234
 spindle cells, 38, 40
- Seminomas, 273, 275–277
 cell block, 275, 276
 large germinal cells, admixed lymphocytes and tigrisoid background, 275
 periodic acid–Schiff cytoplasmic positivity, 275, 277
 prominent atypia, 275, 276
- Skin abscess, 61
- Slovenian cancer registry, 3
- Small-cell osteosarcoma, 251, 253
- Soft tissue lesions, 9, 10
- Solitary fibrous tumor (SFT), 211, 215, 216
 ancillary techniques, 212
 cytologic features, 214
 differential diagnosis, 212
 dispersed cells and loosely cohesive clusters, 212
 fibroblast-like tumor cells, 213
 loosely cohesive sheets of fibroblasts, 213
 nuclear size and shape, 214
- Spindle cell rhabdomyosarcoma, 54
- Spindle cells
 dermatofibrosarcoma protuberans, 38–40
 fibromatosis, 38, 39
 infantine fibrosarcoma, 38, 41, 42
 MPNST, 38, 42, 43
 schwannoma, 38, 40, 41
- Spirochetes, 67–68
- Sporothrix*, 86
- SS. *See* Synovial sarcoma (SS)
- Strongyloidosis, 77
- Subependymal giant cell astrocytoma (SEGA), 332, 334
 differential diagnosis, 334
 neoplastic cells, 334
- Superficial fibromatosis, 206, 208
- Superficial low-grade spindle-cell tumor, 2
- Supraclavicular palpable malignant tumor, 24
- Synovial sarcoma (SS), 29, 30, 165, 259
 biphasic, 259
 cell blocks, 262, 263
 cytologic features, 262
 cytomorphology, 259–263
 differential diagnosis, 264
 monophasic, 259–262
 poorly differentiated SS, 259, 263
- Syphilis, 67
- cell block, 272, 274
 fat and mesodermal structures, 273
 immature teratoma, 272, 274
 somatic type malignancy, neuroendocrine carcinoma, 275
 tubules and epithelial elements, 272, 273
- Thoracic tumors, 6
- Thyroglossal duct cyst
 differential diagnosis of, 291
 fine needle aspiration of, 291
 thyroid scintigraphy, 290
- Thyroid tumors
 benign follicular nodule, 291
 BSRTC, 290
 categories, 289
 chronic lymphocytic thyroiditis, 291–292
 diagnostic accuracy, sensitivity and specificity, 303
 follicular adenoma, 292–293
 follicular carcinoma, 293–294
 histological classification, 289
 incidence of, 289
 medullary thyroid carcinoma, 299–300
 papillary thyroid carcinoma, 294–299
 poorly differentiated thyroid carcinoma, 300–301
 risk factors, 289
 thyroglossal duct cyst, 291
 ultrasonography, 290
 undifferentiated thyroid carcinoma, 301–303
- Toxoplasma gondii*, 76
- Trematodes, 77
 biliary and pancreatic, 79
 gastrointestinal and urinary tract, 80
 pulmonary, 79
- Treponema pallidum*, 67
- Tuberculosis, 64–65
- Tuberous sclerosis complex (TSC), 334
- U**
- Undifferentiated carcinoma of nasopharyngeal type (UCNT), 6, 267, 268
 ancillary techniques, 267
 clinical features, 267
 cytomorphology
 Regaud type, 267, 268
 Schminke type, spindle-shaped cells, Papanicolaou, 267, 268
 differential diagnosis, 267, 268
- Undifferentiated thyroid carcinoma (UTC), 301–303
 ancillary techniques, 302
 differential diagnosis, 302
- Unpigmented hyphal fungi, 89–90
- V**
- Vibrio vulnificus*, 68
- Viruses
 EBV, 71
Herpesvirus 8, 72
 HPV, 70
- W**
- Waldeyer ring, 314
- Wiedemann-Beckwith syndrome, 7
- Wilms' tumor. *See* Nephroblastoma
- T**
- Taenia*, 82
- T-cell/histiocyte-rich large B cell lymphoma (TCHRLBCL), 308, 314
- Teratoma

Y

Yaws, 67

Yeasts

Candida, 87*Cryptococcus*, 85, 86*Histoplasma capsulatum*, 83–85*Pneumocystis*, 86*Rhinosporidium seeberi*, 88*Sporothrix*, 86

Yolk sac tumors (YST)

cluster of tumor cells, 277, 279

loose clusters, 277, 278

perivascular arrangement of tumor cells, 277, 278

pseudo papillary arrangement, 279, 280

three-dimensional round clusters and eosinophilic matrix, 277

watery myxoid-like material, 279

Z

Zygomycosis, 89